|  |  |
| --- | --- |
|  | **Dr Graham Kelly B.Sc(Hons),B.VSc(Hons)**  **Executive Director & CEO**  Dr Graham Kelly is the founder and previous CEO and Chairman of ASX-listed and NASDAQ-listed companies, Novogen Ltd and Marshall Edwards Inc. Both companies were built on the concept of benzopyran drug technology that emanated from his 25 years in cancer research in the Department of Surgery, The University of Sydney, and the German Central Cancer Research Institute, Heidelberg, (Germany) and for which he held all relevant patents.  Dr Kelly personally oversaw the design and implementation of thirty-three Phase I and II clinical trials, and a multi-national Phase III trial in conjunction with the US FDA.  He has been awarded an Adjunct Professorship by the University of Sydney. |
| John-OConnor_400.jpg | **John P O’Connor BEc., MAICD**  **Non-Executive Director, Deputy Chairman**  Mr John O’Connor has over 30 year’s experience in the financial industry and was appointed to the Novogen board inpe May 2012.  He has held numerous management roles as a fund manager and stockbroker in the UK, US and Australia and also a partnership in a securities business.  He has been a consultant to several biotech companies, including Novogen Limited and Marshall Edwards Inc., assisting with fundraising.  Mr O’Connor served on the Board of Lonsec Securities, a Zurich Insurance owned business, for several years. |
| http://static.squarespace.com/static/52efad36e4b0e172529aa02e/t/5332250de4b02ebf3fbb8d7d/1395795214828/?format=500w | **Steven Coffey CA**  **Non-Executive Director**  Mr Steven Coffey is a Chartered Accountant, having spent his career in public practice since graduating from NSW University in 1983. He has been a partner in the chartered accounting firm Watkins Coffey Martin since 1993.  Mr Coffey is a registered company auditor and audits a number of large private companies as well as not for profit entities. He has previously served on the board of an Australian listed public company and is currently a board member of private family foundation. |
| http://static.squarespace.com/static/52efad36e4b0e172529aa02e/t/53359bd3e4b05b79d04d3060/1396022228485/?format=500w | **Professor Peter Gunning B.Sc(Hons),Ph.D**  **Non-executive Director**  Professor Gunning is the Head of the Oncology Research Unit in the School of Medical Sciences and Deputy Dean (Research) in the Faculty of Medicine at the University of New South Wales. His research is focused on the development of new therapeutic strategies for the treatment of childhood cancer. These strategies target the skeleton of the cancer cell and build on the principles of cell architecture that Professor Gunning's group has discovered over the last 20 years.  Professor Gunning has published over 100 primary research articles and has recently edited the first book devoted to his field of research.  Previous appointments have included leadership roles as Chair of the Division of Research at The Children’s Hospital at Westmead, Chair of the Westmead Research Hub. Executive, member of the Board, NSW Cancer Institute and Chair, Board of Bio-Link, a company established by the NSW Government to support commercialisation of biomedical intellectual property. |